Last reviewed · How we verify
Autologous Hematopoietic Stem Cell Transplant
Autologous Hematopoietic Stem Cell Transplant is a Stem cell therapy Small molecule drug developed by Gary A Levy, O. Ont. MD. FRCP AGAF. It is currently in Phase 2 development for Relapsed or refractory Hodgkin lymphoma, Relapsed or refractory non-Hodgkin lymphoma, Multiple myeloma. Also known as: HSCT.
Autologous Hematopoietic Stem Cell Transplant involves collecting a patient's stem cells, treating them to eliminate cancer cells, and then reinfusing them to help the body produce healthy blood cells.
Autologous Hematopoietic Stem Cell Transplant involves collecting a patient's stem cells, treating them to eliminate cancer cells, and then reinfusing them to help the body produce healthy blood cells. Used for Relapsed or refractory Hodgkin lymphoma, Relapsed or refractory non-Hodgkin lymphoma, Multiple myeloma.
At a glance
| Generic name | Autologous Hematopoietic Stem Cell Transplant |
|---|---|
| Also known as | HSCT |
| Sponsor | Gary A Levy, O. Ont. MD. FRCP AGAF |
| Drug class | Stem cell therapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This process allows the body to regenerate its own healthy blood cells, replacing those damaged by cancer treatment or disease. The treated stem cells then help the body recover from the effects of chemotherapy or radiation therapy.
Approved indications
- Relapsed or refractory Hodgkin lymphoma
- Relapsed or refractory non-Hodgkin lymphoma
- Multiple myeloma
- Acute myeloid leukemia
- Breast cancer
- Lung cancer
- Melanoma
- Multiple sclerosis
- Sickle cell disease
- Severe autoimmune disorders
Common side effects
- Infection
- Bleeding
- Nausea and vomiting
- Fatigue
- Pain
- Hypersensitivity reactions
- Organ toxicity
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) (PHASE1, PHASE2)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma (PHASE2)
- HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 (PHASE2)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous Hematopoietic Stem Cell Transplant CI brief — competitive landscape report
- Autologous Hematopoietic Stem Cell Transplant updates RSS · CI watch RSS
- Gary A Levy, O. Ont. MD. FRCP AGAF portfolio CI
Frequently asked questions about Autologous Hematopoietic Stem Cell Transplant
What is Autologous Hematopoietic Stem Cell Transplant?
How does Autologous Hematopoietic Stem Cell Transplant work?
What is Autologous Hematopoietic Stem Cell Transplant used for?
Who makes Autologous Hematopoietic Stem Cell Transplant?
Is Autologous Hematopoietic Stem Cell Transplant also known as anything else?
What drug class is Autologous Hematopoietic Stem Cell Transplant in?
What development phase is Autologous Hematopoietic Stem Cell Transplant in?
What are the side effects of Autologous Hematopoietic Stem Cell Transplant?
Related
- Drug class: All Stem cell therapy drugs
- Manufacturer: Gary A Levy, O. Ont. MD. FRCP AGAF — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory Hodgkin lymphoma
- Indication: Drugs for Relapsed or refractory non-Hodgkin lymphoma
- Indication: Drugs for Multiple myeloma
- Also known as: HSCT
- Compare: Autologous Hematopoietic Stem Cell Transplant vs similar drugs
- Pricing: Autologous Hematopoietic Stem Cell Transplant cost, discount & access